March 23, 2021

Selexis and Tallac Therapeutics Collaborate to Advance Tallac’s Pipeline of Novel Immunotherapies in Oncology

Read More
March 18, 2021

SpyBiotech Licenses Selexis Best-in-Class Cell Line Development Technologies to Advance Human Cytomegalovirus VLP Vaccine Program

Read More
March 16, 2021

Selexis Enters Service Agreement with Pandion Therapeutics to Advance Pandion Antibody

Read More

Media Downloads